Tarrytown, New York and Paris - January 9, 2015 - Sanofi and Regeneron Pharmaceuticals, Inc.
today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess
alirocumab administered every four weeks, met their primary efficacy endpoints. The trials
compared the reduction from baseline in low-density lipoprotein cholesterol (LDL-C, or “bad”
cholesterol) at 24 weeks with alirocumab versus placebo in patients with hypercholesterolemia.
Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase
subtilisin/kexin type 9).
en.sanofi.com/Images/38079_20150109_AlirocumabTopline_en.pdf
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.